Valve replacement

Global Surgical Heart Valve Management Products Markets, 2018 & 2019-2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 16, 2019
Health, Surgery, Cardiology, Medical devices, Cardiac surgery, Medicine, Medical specialties, Clinical medicine, Heart valve repair, Valvular heart disease, Aortic valvuloplasty, Regurgitation, Mitral valve annuloplasty, Valve replacement, Heart valve, Tricuspid valve stenosis

The "Surgical Heart Valve Management Products" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Surgical Heart Valve Management Products" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive medical market and technology report, which covers the US, five major EU markets, Japan, and RoW markets from 2018-23, provides an overview and in-depth market analysis of the surgical heart valve products used in the treatment of heart valve stenosis, regurgitation, and other valvular disorders.
  • These products include surgical heart valve repair (annuloplasty) systems, surgical heart valve replacement products, and percutaneous balloon valvuloplasty (PBV) systems.
  • Global sales of these products totaled more than $2.0bn in 2018, and are expected to experience relatively flat growth over the forecast period, with PBV sales experiencing robust double-digit growth and heart valve repair and replacement product sales declining.

Medtronic Announces Early Feasibility Trial for Intrepid™ Transcatheter Mitral Valve Replacement System with Transfemoral Transseptal Approach

Retrieved on: 
Friday, September 27, 2019
Medical specialties, Medicine, Cardiac surgery, Circulatory system, Cardiology, Mitral valve replacement, Regurgitation, Mitral valve, Valvular heart disease, Mitral insufficiency, Valve replacement, Heart valve

DUBLIN, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) todayannounced it has received U.S. Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) for its Intrepid transcatheter mitral valve replacement (TMVR) system using a minimally-invasive transfemoral access approach.

Key Points: 
  • DUBLIN, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) todayannounced it has received U.S. Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) for its Intrepid transcatheter mitral valve replacement (TMVR) system using a minimally-invasive transfemoral access approach.
  • The prospective, multi-center, non-randomized EFS will evaluate the safety and performance of the Intrepid TMVR System with the transfemoral approach in patients with severe, symptomatic mitral regurgitation (MR) who are ineligible for conventional mitral valve surgery.
  • Mitral regurgitation (MR) is the most common heart valve disease in the United States, affecting an estimated four million people.
  • Medtronic believes that transcatheter mitral valve replacement will have a vital role in treating patients with mitral valve diseaseand this early feasibility study is another step forward in our Intrepid program, said Nina Goodheart, vice president and general manager, Structural Heart business, which is part of the Cardiac and Vascular Group at Medtronic.

Imminent Decision on Medicare Coverage of TAVR; New Research Shows Patients Benefit in Recovery

Retrieved on: 
Friday, June 21, 2019
Medicine, Medical specialties, Cardiac surgery, Clinical medicine, Cardiology, Percutaneous aortic valve replacement, Aortic valve replacement, Valve replacement, Aortic valve, Valvular heart disease, Heart valve, Hybrid cardiac surgery

A new analysis of the SURTAVItrial shows that two years after treatment, valve disease patients treated with TAVR (transcatheter aortic valve replacement) had significant improvement in a 6-minute walk test compared to patients who were treated surgically.

Key Points: 
  • A new analysis of the SURTAVItrial shows that two years after treatment, valve disease patients treated with TAVR (transcatheter aortic valve replacement) had significant improvement in a 6-minute walk test compared to patients who were treated surgically.
  • TAVR patients also had better functional status at the 30-day mark as well.
  • Currently, Medicare coverage determines which hospitals may provide TAVR, based on thenumber of surgical and interventional cardiac procedures they do each year.
  • Heart Valve Voice US is a nonprofit patient advocacy organization that provides a voice to those living with heart valve disease and educates patients and the public about heart valve disease.

Tiara™ Featured in Presentation at 11th Annual TVT 2019

Retrieved on: 
Monday, June 17, 2019
Cardiac surgery, Medicine, Medical specialties, Heart, Valvular heart disease, Heart valves, Mitral valve replacement, Mitral valve, Valve replacement, Heart valve, John G. Webb, MitraClip

VANCOUVER, June 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara ("Tiara") transcatheter mitral valve replacement device was featured in a presentation at the 11th Annual Transcatheter Valve Therapy Conference ("TVT 2019").

Key Points: 
  • VANCOUVER, June 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara ("Tiara") transcatheter mitral valve replacement device was featured in a presentation at the 11th Annual Transcatheter Valve Therapy Conference ("TVT 2019").
  • TVT 2019 is part of The Structural Heart Disease Summit held June 12-15 in Chicago, Illinois.
  • "We are pleased to report yet another comprehensive clinical update on our Tiara clinical studies to the Medical community, this time in the USA" commented Fred Colen, Neovasc's President and Chief Executive Officer.
  • Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.

Global Prosthetic Heart Valves Market Analysis 2015-2019 & Forecast to 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 13, 2019
Health, Cardiology, Medical devices, Medical specialties, Medicine, Cardiac surgery, Clinical medicine, Heart valve, Aortic valve, Valve replacement

Pediatric Heart Valve Disease - Repair vs. Replacement

Key Points: 

Pediatric Heart Valve Disease - Repair vs. Replacement
Biological Valve Options - Better, Yet Need Improvements
TAVR - A Review of Present, Present and Future Prospects
Novel Heart Procedure for AS, Vancouver 3M Clinical Pathway

BioStable Science & Engineering Surpasses 500 Patients Treated Worldwide with the HAART Devices

Retrieved on: 
Friday, May 3, 2019
Surgery, Health, Biotechnology, Cardiology, Hospitals, Medical devices, Cardiac surgery, Medicine, Medical specialties, Clinical medicine, Aortic valve repair, Aortic valve replacement, Aortic valve, Heart valve repair, Mitral valve annuloplasty, Valve replacement, Apicoaortic Conduit, Percutaneous aortic valve replacement

BioStable Science & Engineering,a medical technology company focused on products for aortic valve repair for the treatment of aortic insufficiency, today announced that over 500 patients worldwide have now been treated using the HAART Aortic Annuloplasty Device.

Key Points: 
  • BioStable Science & Engineering,a medical technology company focused on products for aortic valve repair for the treatment of aortic insufficiency, today announced that over 500 patients worldwide have now been treated using the HAART Aortic Annuloplasty Device.
  • Many cardiothoracic surgeons recognize that the young aortic insufficiency patient population cannot be treated with percutaneous aortic valve replacement devices and should be treated surgically with aortic valve repair whenever possible.1 The HAART Aortic Annuloplasty Devices are enabling surgeons to perform successful aortic valve repair across a broad spectrum of this underserved patient population, says John Wheeler, President and CEO of BioStable Science & Engineering.
  • To date, over 50 heart centers have adopted the HAART technology including five new hospitals in April alone performing their first HAART implant.
  • BioStable Science & Engineering is a cardiovascular device company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.

Global Heart Valve Repair and Replacement Devices Market 2019-2023 | 16% CAGR Projection over the Next Five Years | Technavio

Retrieved on: 
Monday, April 22, 2019
Surgery, Health, Travel, Cardiology, Other Travel, Hospitals, Medical devices, Medical Supplies, Cardiac surgery, Medicine, Medical specialties, Clinical medicine, Valve replacement, Heart valve repair, Valve Corporation, Valve

This global heart valve repair and replacement devices market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.

Key Points: 
  • This global heart valve repair and replacement devices market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
  • Global heart valve repair and replacement devices market: Technological advances
    The heart valve repair and replacement devices market has been witnessing several technological advances over the past decade.
  • This is fueling the demand for heart valve therapies such as heart valve repair and replacement.
  • Global heart valve repair and replacement devices market: Segmentation analysis
    This market research report segments the global heart valve repair and replacement devices market by product (heart valve replacement devices, and heart valve repair devices) and geographic regions (North America, Europe, Asia, and ROW).

In the report the structural heart market, the market is expected to reach US$ 13,850.2 Mn in 2025 from US$ 6,406.3 in 2017

Retrieved on: 
Monday, March 25, 2019
Medicine, Cardiac surgery, Medical specialties, Heart, Heart valves, Cardiology, Mitral valve, Aortic valve, Percutaneous aortic valve replacement, Valve replacement, Interventional cardiology, Hybrid cardiac surgery

NEW YORK, March 25, 2019 /PRNewswire/ -- In the report the structural heart market, the market is expected to reach US$ 13,850.2 Mn in 2025 from US$ 6,406.3 in 2017.

Key Points: 
  • NEW YORK, March 25, 2019 /PRNewswire/ -- In the report the structural heart market, the market is expected to reach US$ 13,850.2 Mn in 2025 from US$ 6,406.3 in 2017.
  • However, the trend of the technological advancement for the structural heart devices are likely to robust the growth of structural heart market in the forecast period.
  • The procedure segment of the structural heart market includes surgical aortic valve replacement, transcatheter aortic valve replacement, mitral repair and left atrial appendage closure and others.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the structural heart market.

Low-Risk Patients Benefit from Minimally Invasive Transcatheter Aortic Valve Replacement

Retrieved on: 
Sunday, March 17, 2019
Medicine, Medical specialties, Cardiac surgery, Clinical medicine, Percutaneous aortic valve replacement, Aortic valve replacement, Aortic valve, Valve replacement, Aortic stenosis, Edwards Lifesciences, Mitral valve repair

CHICAGO, March 17, 2019 /PRNewswire/ --Patients suffering from severe aortic stenosis once had a single option for treatment open-heart surgery to replace their diseased valve.

Key Points: 
  • CHICAGO, March 17, 2019 /PRNewswire/ --Patients suffering from severe aortic stenosis once had a single option for treatment open-heart surgery to replace their diseased valve.
  • Results from a New England Journal of Medicine paper, released March 17 and co-authored by S. Chris Malaisrie, MD , cardiac surgeon at Northwestern Medicine and co-chair of the PARTNER 3 case review board, demonstrated that patients who were at low-risk for surgical complications still benefited from a minimally invasive, transcatheter aortic valve replacement (TAVR).
  • The results are expected to expand TAVR as an option for patients who are at low risk for surgical aortic valve replacement, allowing them to reap the benefits of valve replacement without undergoing surgery.
  • Patients participating in the PARTNER 3 low-risk TAVR trial were randomly selected to either receive the transcathether valve or to replace the valve through open-heart surgery.

Neovasc to Announce Year Ended December 31, 2018 Financial Results on Thursday, March 21

Retrieved on: 
Wednesday, March 13, 2019
Medicine, Cardiac surgery, Medical specialties, Clinical medicine, Valve replacement, Mitral valve replacement, Minimally invasive procedure, Mitral valve, NASDAQ, Boston Scientific

VANCOUVER, March 13, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that, due to the public offering of common stock announced on March 12, 2019, it will now report financial results for the year ended December 31, 2018 and host a conference call and webcast at 4:30 pm Eastern Time on Thursday, March 21, 2019.

Key Points: 
  • VANCOUVER, March 13, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that, due to the public offering of common stock announced on March 12, 2019, it will now report financial results for the year ended December 31, 2018 and host a conference call and webcast at 4:30 pm Eastern Time on Thursday, March 21, 2019.